Probiotic Preparation Containing Akkermansia Muciniphila Akk11 Strain for Alleviating Hypertension
Summary
USPTO published patent application US20260108565A1 on April 23, 2026, covering a probiotic preparation combining Akkermansia muciniphila Akk11 strain with Lactobacillus rhamnosus LRa05 strain for alleviating hypertension. The application, originally filed July 9, 2024 under application number 18879015, names Shuguang Fang, Yao Dong, Yunjiao Zhao, Zhonghui Gai, and Jianguo Zhu as inventors. The CPC classifications include A61K 35/741, A61P 9/12, and A61K 2035/115, indicating pharmaceutical preparations containing probiotics and anti-hypertensive agents.
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
USPTO published patent application US20260108565A1 for a probiotic preparation containing Akkermansia muciniphila Akk11 strain combined with Lactobacillus rhamnosus LRa05 strain. The application claims synergistic efficacy in alleviating hypertension through enhanced blood pressure regulation, improved renal function markers (urinary protein, serum creatinine), and optimized oxidative stress response.
This patent application publication does not create immediate compliance obligations for pharmaceutical or probiotic manufacturers. Competitors developing similar microbiome-based hypertension treatments should monitor the prosecution of this application to assess potential freedom-to-operate implications in the probiotic and pharmaceutical space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PROBIOTIC PREPARATION CONTAINING AKKERMANSIA MUCINIPHILA AKK11 STRAIN FOR ALLEVIATING HYPERTENSION AND USE THEREOF
Application US20260108565A1 Kind: A1 Apr 23, 2026
Inventors
Shuguang FANG, Yao DONG, Yunjiao ZHAO, Zhonghui GAI, Jianguo ZHU
Abstract
Provided is a probiotic preparation containing an Akkermansia muciniphila Akk11 strain for alleviating hypertension, and the probiotic preparation includes an Akkermansia muciniphila Akk11 strain and a Lactobacillus rhamnosus LRa05 strain, which are found to have potential interactions between the two, and to be able to complement each other in terms of their efficacy in alleviating hypertension synergistically; specifically manifested in: significantly enhancing the ability of blood pressure regulation, and optimizing the mechanism of blood pressure regulation; significantly regulating the levels of urinary protein and serum creatinine, which are markers of renal function, effectively alleviating renal function, and alleviating renal damage caused by hypertension; and significantly optimizing the response to oxidative stress, and enhancing the antioxidant defense ability of the body.
CPC Classifications
A61K 35/741 A61P 9/12 A61K 2035/115
Filing Date
2024-07-09
Application No.
18879015
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.